New drug shows promise for rare immune disorders
NCT ID NCT04641442
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times
Summary
This study tests a drug called MAS825 in people with rare genetic diseases that cause severe inflammation. The goal is to see if the drug can prevent sudden flare-ups of symptoms. The trial involves 17 participants and uses a placebo for comparison.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bambino Gesu Hospital
Roma, RM, 00165, Italy
-
Centrum detske revmatologie a autoinflamatornich onemocneni
Prague, CZ, 121 00, Czechia
-
Children´s Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Novartis Investigative Site
Prague, 128 08, Czechia
-
Novartis Investigative Site
Paris, 75970, France
-
Novartis Investigative Site
Chiba, 266-0007, Japan
-
Novartis Investigative Site
Madrid, 28046, Spain
-
Novartis Investigative Site
London, NW3 2QG, United Kingdom
-
Seattle Children´s Hospital
Seattle, Washington, 98105, United States
-
Texas Children´s Hospital
Houston, Texas, 77030, United States
-
Ustav Imunologie 2 LF UK a FN Motol
Prague, 150 06, Czechia
Conditions
Explore the condition pages connected to this study.